NASDAQ : ANGO

AngioDynamics, Inc.

$15.759 USD

$0.01 (0.06%)

Volume
24.49K
Average Volume
439.52K
Market Capitalization
$651.36M
P/E Ratio
-17.91
Dividend Yield
0.00%
Price Target
$19.50
Year High
$16.05
Year Low
$8.45
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$2.19
Company Overview

NASDAQ

James C. Clemmer

Medical - Instruments & Supplies

Healthcare

ANGO

632

US

USD

https://www.angiodynamics.com

518 795 1400

03475V101

0001275187

Liquidity Metrics

0.00

2.19

1.49

0.72

0.00

Sales & Valuation

$320.17M

2.03

3.83

1282.20

0.01

Profitability

-$0.88

-$36.74M

-11.48%

-11.34%

-21.01%

-13.75%

P/E Metrics

-17.91

1.50

1.50

Analyst Price Target & Rating

$19.50

$20.00

$19.00

Sell

2/5

11 Analysts

-19.18%

Financial Health Scores

2.75

5/9

$88.68M

$267.16M

$96.34M

-$36M

Key Metrics (TTM)

$594.64M

1.86

-16.52

2.19

-21.01%

-20.75%

-5.64%

0.08%

108 days

Company Executives
Name Title
Warren G. Nighan Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain
Laura Piccinini Senior Vice President & GM of Cardiovascular and International
Jake Brumbaugh Global Vice President for Marketing-Oncology
Saleem Cheeks Vice President of Communications
Marna I. Bronfen-Moore Senior Vice President of Human Resources
Kim L. Seabury Senior Vice President of Information Technology
Chad T. Campbell Senior Vice President and GM of Oncology & Interventional Devices
Juan Carlos Serna Senior Vice President of Scientific & Clinical Affairs
Benjamin H. Davis Senior Vice President of Business Development & Strategy
Stephen A. Trowbridge Executive Vice President & Chief Financial Officer
James C. Clemmer Chief Executive Officer, President & Director
Lawrence T. Weiss Senior Vice President, Chief Legal Officer & Corporate Secretary
Poll Results

No votes yet today — be the first to share your view!

About AngioDynamics, Inc. (NASDAQ:ANGO) Stock

AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, g ... uidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.

Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?

2026-08-06 15:20:51

AngioDynamics' Med Tech growth and reimbursement gains strengthen its outlook, but tariffs, rising costs and execution risks keep the buy case uncertain.

ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus

2026-08-06 15:16:06

AngioDynamics' fiscal 2027 outlook hinges on Med Tech growth offsetting flat device sales as tariffs, spending and losses pressure margins.

ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?

2026-08-06 15:11:03

AngioDynamics' 33.5% three-month rally rests on Med Tech growth, but valuation, tariffs and negative earnings keep execution risks high.

AngioDynamics to Participate in Upcoming Investor Conferences

2026-07-28 09:00:00

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular syste

AngioDynamics to Participate in Upcoming Investor Conferences

2026-07-28 08:30:00

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its management team is scheduled to participate in the following upcoming investor conferences: 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference Monday, August 10, 2026 Canaccord Genuity's 4.

AngioDynamics: Growth Is Working, Price Knows It (Rating Downgrade)

2026-07-16 11:07:15

AngioDynamics develops tools for minimally invasive procedures across blood flow, blocked arteries, and prostate cancer treatment. Key offerings include AlphaVac and AngioVac for clot removal, Auryon for arterial plaque, and NanoKnife for prostate cancer. After a prolonged period of stagnation, ANGO shares are finally showing signs of positive momentum.

AngioDynamics Q4 Earnings Beat Estimates, Gross Margin Expands

2026-07-15 11:30:34

ANGO's Q4 FY26 revenues rise 8% as Med Tech surges, while its adjusted loss beats estimates and FY27 sales guidance tops consensus.

AngioDynamics, Inc. (ANGO) Q4 2026 Earnings Call Transcript

2026-07-14 10:59:05

AngioDynamics, Inc. (ANGO) Q4 2026 Earnings Call Transcript

Frequently Asked Questions

What is the current AngioDynamics, Inc. (ANGO) stock price?

AngioDynamics, Inc.(NASDAQ:ANGO) stock price is $15.759 in the last trading session. During the trading session, ANGO stock reached the peak price of $16.05 while $8.45 was the lowest point it dropped to. The percentage change in ANGO stock occurred in the recent session was 0.06% while the dollar amount for the price change in ANGO stock was $0.01.

ANGO's industry and sector of operation?

The NASDAQ listed ANGO is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector.

Who are the executives of ANGO?

Warren G. Nighan | Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain
Laura Piccinini | Senior Vice President & GM of Cardiovascular and International
Jake Brumbaugh | Global Vice President for Marketing-Oncology
Saleem Cheeks | Vice President of Communications
Marna I. Bronfen-Moore | Senior Vice President of Human Resources

How many employees does ANGO have?

Number of ANGO employees currently stands at 632. ANGO operates from 14 Plaza Drive, Latham, NY 12110, US.

Link for ANGO official website?

Official Website of ANGO is: https://www.angiodynamics.com

How do I contact ANGO?

ANGO could be contacted at phone #518 795 1400 and can also be accessed through its website. ANGO operates from 14 Plaza Drive, Latham, NY 12110, US.

How many shares of ANGO are traded daily?

The average number of ANGO shares traded daily for last 3 months was 439.52K.

What is the market cap of ANGO currently?

The market value of ANGO currently stands at $651.36M with its latest stock price at $15.759